T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator Production

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Miernikiewicz, Paulina ^a   Dabrowska, Krystyna ^a   Piotrowicz, Agnieszka ^a   Owczarek, Barbara ^a   Wojas Turek, Justyna ^a   Kicielińska, Jagoda ^a   Rossowska, Joanna ^a   Pajtasz Piasecka, Elzbieta ^a   Hodyra, Katarzyna ^a   Macegoniuk, Katarzyna ^a   Rzewucka, Kamila ^a   Kopciuch, Agnieszka ^a   Majka, Tomasz ^a   Letarov, Andrey ^b   Kulikov, Eugene ^b   Maciejewski, Henryk ^c   Górski, Andrzej ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WINOGRADSKY INSTITUTE OF MICROBIOLOGY   (Russian Federation)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CAPSID PROTEIN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN GP23; GLYCOPROTEIN GP24; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; REACTIVE OXYGEN METABOLITE; SOC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE T4; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; BACTERIOPHAGE T4; CAPSID PROTEINS; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES;

EID: 84881598843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071036     Document Type: Article

References (35)

1. Thannickal VJ, Fanburg BL, (2000) Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279(6): L1005-28.
2. Mogensen TH, Paludan SR, (2001) Molecular Pathways in Virus-Induced Cytokine Production. Microbiol Mol Biol Rev 65(1): 131-50.
3. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 12(10): 1203-7.
4. Lam WY, Yeung AC, Chan PK, (2011) Apoptosis, cytokine and chemokine induction by non-structural 1 (NS1) proteins encoded by different influenza subtypes. Virol J 21 8: 554.
5. Schwarz KB, (1996) Oxidative stress during viral infection: a review. Free Radic Biol Med 21(5): 641-9.
6. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, et al. (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280(45): 37481-8.
7. Li Y, Boehning DF, Qian T, Popov VL, Weinman SA, (2007) Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J. 21(10): 2474-85.
8. Maura D, (2011) Debarbieux (2011) Bacteriophages as twenty-first century antibacterial tolls for food and medicine. Appl Microbiol Biotechnol 90(3): 851-9.
9. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D, (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51: 2765-73.
10. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, et al. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis. 187(4): 613-24.
11. Mann NH, (2008) The potential of phages to prevent MRSA infections. Res Microbiol. 159(5): 400-5.
12. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, et al. (2010) Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 201(7): 1096-104.
13. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, et al. (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 51(2): 446-52.
14. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, et al. (2012) Clinical Aspects of Phage Therapy. Adv Virus Res 83, 73-121.
15. Bruttin A, Brussow H, (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 49(7): 2874-8.
16. Górski A, Kniotek M, Perkowska-Ptasińska A, Mróz A, Przerwa A, et al. (2006) Bacteriophages and transplantation tolerance. Transplant Proc 38(1): 331-3.
17. Przerwa A, Zimecki M, Switala-Jelen K, Dabrawska K, Krawczyk E, et al. (2006) Effect of bacteriophages on free radicals productions and phagocitic functions. Med Microbiol and Immunol 195: 143-150.
18. Górski A, Weber-Dabrowska B, (2005) The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62: 511-9.
19. Górski A, Mie{ogonek}dzybrodzki R, Borysowski J, Da{ogonek}browska K, Wierzbicki P, et al. (2012) Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res. 83: 41-71.
20. Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, et al. (2003) Bacteriophage T4 Genome. Microbiol Mol Biol Rev 67(1): 86-156.
21. Fokine A, Leiman P, Shneider MM, Ahvazi B, Boeshans KM, et al. (2005) Structural and functional similarities between the capsid proteins of bacteriophages T4 and HK97 point to a common ancestry. Proc Natl Acad Sci USA 102(20): 7163-8.
22. Black LW, Showe MK, Steven AC, (1994) Morphogenesis of the T4 Head. In: Karam JD, editor. Molecular biology of bacteriophage T4. American Society for Microbiology, Washington, D. C: 218-258.
23. Rao VB, Black LW, (2010) Structure and assembly of bacteriophage T4 head. Virol J. 3 7: 356.
24. Allen RC (1986) Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. In DeLuca MA editor. Bioluminescence and chemiluminescence, part B. Methods in Enzymology, vol 133. Academic press, London, 449-493.
25. Łukasiewicz J, Ługowski C (2003) Biologic activity of lipopolysaccharides. Postepy Hig Med Dosw. 57(1):33-53. [Article in Polish].
26. Clark JR, March JB, (2004) Bacterial viruses as human vaccines? Expert Rev Vaccines 3(4): 463-76.
27. Jiang J, Abu-Shilbayeh L, Rao VB, (1997) Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect. Immun. 65: 4770-4777.
28. Ren S, Fengyu, Zuo S, Zhao M, Wang X, et al. (2011) Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine 5 29(34): 5802-11.
29. Sathaliyawala T, Rao M, Maclean DM, Birx DL, Alving CR, et al. (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol. 80(15): 7688-98.
30. Krisch HM, Comeau AM, (2008) The immense journey of bacteriophage T4- from d'Hérelle to Delbrück and then to Darwin and beyond. Res Microbiol 159(5): 314-24.
31. Letarov AV, Kulikov E, (2009) The bacteriophages in human- and animal body-associated microbial communities. J Appl Microbiol 107(1): 1-13.
32. Boratyński J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska M, Poźniak G, et al. (2004) Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9(2): 253-9.
33. Adams MH (1959) Bacteriophages. New York: Inter Science Publ, New York, USA.
34. Westphal O, Jann K (1965) Bacterial lipopolysaccharides: extraction with phenol-water and further applications of procedure. In: Whisler, R.L. (Ed.), Methods in Carbohydrate Chemistry, vol. 5. Academic Press, Inc., New York, 83-91.
35. van Crevel R, van der Ven-Jongerijg J, Netea MG, deLange W, Kullberg BJ, et al. (1999) Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis. J Immunol Methods 222(1-2): 145-53.